Floatz logo

Torl-1-23

Endometrioid Ovarian Cancer

TORL Biotherapeutics, LLCPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

43 Active assets in the Endometrioid Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Olaparib
University of Colorado, Denver
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Genelux Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

Torl-1-23 is also rated in:

primary peritoneal carcinomaDormant
B
Indicative ·
60 / 100
View asset →
ovarian carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
fallopian tube cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →